Kventiax Ep

Quetiapine, the active ingredient in Kventiax Ep, is an atypical antipsychotic presented as an oral tablet for systemic use. It is prescribed for the management of schizophrenia, bipolar disorder and as an adjunct in major depressive disorder in adult patients.

GNH USA supplies Kventiax Ep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from transparent pricing, comprehensive documentation, and support throughout the import and distribution process.

Quetiapine is used in psychiatric disorders that involve dysregulation of dopamine and serotonin pathways. - Schizophrenia: reduces positive and negative symptoms, improving overall functioning. - Bipolar disorder (manic and depressive episodes): stabilizes mood and decreases frequency of episodes. - Adjunctive treatment of major depressive disorder: enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness or sedation. - Dry mouth. - Constipation. - Weight gain. - Orthostatic hypotension. - Dizziness.

Serious or Rare Side Effects: - Agranulocytosis. - Neuroleptic malignant syndrome. - Tardive dyskinesia. - Severe hypotension. - Suicidal thoughts or behaviors. - Pancreatitis.

Before initiating therapy, clinicians should evaluate several safety considerations. - Assess cardiovascular status: monitor blood pressure and heart rate, especially during initiation. - Screen for metabolic risk: evaluate weight, glucose and lipid profile regularly. - Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal symptoms. - Use caution in elderly: increased sensitivity to sedation and orthostatic falls. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Quetiapine interacts with several drug classes; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise quetiapine plasma levels, increasing toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Antihypertensive agents: enhanced hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower quetiapine levels, reducing efficacy. - Other antipsychotics: increased risk of QT prolongation. - Alcohol: may intensify sedation and impair cognition.